Abstract
Objective: To explore the possibility of using traditional Chinese medicine (TCM) in treating β-thalassemia, its clinical effect and molecular mechanism of the action.Methods: According to the TCM theory of “Shen producing marrow”, the composite recipe, Yisui Shenxueling Granule (YSSXL), consisting of Chinese drugs for nourishing Shen and supplementing marrow (NS & SM) was given orally to 78 patients with β-thalassemia (49 of the severe type and 29 of moderate type), 3 times a day, 10 g each time (for children, the dose would be reduced properly), with 3 months as one therapeutic course, and no blood transfusion used in the course. The clinical therapeutic efficacy and hematologic parameters in patients were observed, and systemic gene analysis was conducted with PAGE, PCR, PCR-SSCP, RT-PCR and DNA sequences analysis and mRNA detection, in order to study the molecular mechanism from the relationships between genetic mutation and clinical efficacy, gene expression and its regulation.Results: YSSXL showed obvious therapeutic effect in treating β-thalassemia. Gene analysis revealed that it did not change the genetic mutation type, but could obviously increase hemoglobin, fetal hemoglobin (HbF), γ/(β+γ) globin ratio, γ-globin mRNA expression and GM-CSF mRNA expression in patients, as well as the GM-CSFmRMA in marrow of mice after60Co radiation.Conclusion: YSSXL has a remarkable therapeutic effect on β-thalassemia, and its possible mechanism is its action in unlocking γ-gene, increasing the γ-globin expression and enhancing HbF synthesis so as to compensate for the gene defect. This study has opened a new path for the treatment of β-thalassemia with TCM.
Similar content being viewed by others
References
WANG RX, HUANG YW, ZHANG XH, et al. Further clinical study of “Yisui Shengxueling” in treating β-thalassemia. Chinese Journal of Eugenic and Heredity 1998;6(2): 28–29.
WU ZK, CHEN SH, JIANG BH, et al. The clinical and mechanism study of “Zhongguo Shenfang” on treating β-thalassemia. Pharmacology and Clinicals of Chinese Materia Medica 1991; 7(5): 37–39.
ZHANG ZN. The Standard for Diagnosis and Treatment of Hematopathy. Tianjin: Tianjin Science and Technology Press, 1991: 48–49.
CAO A, Calanello R, Rosatelli MC, et al. Clinical experience of management of β-thalassemia:The Sardinian experience. Seminars in Hematolgy 1996;33(1): 70–73.
HUANG SZ, REN ZR, CHEN MY, et al. Study of hydroxyurea in treating β-thalassemia—Effect of hydroxyurea on globin expression. Chinese Science (B volume) 1994;22(2): 171–174.
LIU DP, LIANG ZQ, AO ZH, et al. Myleran can increase synthesis of hemoglobin in fetal of rhesus monkey. J China Academy of Medical Science 1986; 8: 419–421.
LIU DP, LIANG ZQ, AO ZH, et al. Treatment of severe β-thalassemia (patient) with Myleran. American Journal of Hematology 1990;33: 50–52.
Author information
Authors and Affiliations
Corresponding author
Additional information
This item was supported by National Funds of Natural Sciences (No. 30171199) and Natural Science Foundation of Guangxi Autonomous Region (No. 014402C)
Rights and permissions
About this article
Cite this article
Zhi-kui, W., Su-ping, F., Xin-hua, Z. et al. Clinical efficacy and molecular mechanism of nourishing shen and supplementing marrow principle in treating β-thalassemia. Chin. J. Integr. Med. 9, 248–253 (2003). https://doi.org/10.1007/BF02838606
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02838606